Skip to content
10-Q

Quarterly Report

PROPANC BIOPHARMA, INC. PPCB

0001493152-26-023210

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · May 14, 2026 56.96M sh
Shares Diluted Q3 2026 · Mar 31, 2026 22.43M sh
Shares Diluted Q3 2026 · Mar 31, 2026 15.97M sh
Shares Diluted Q3 2026 · Mar 31, 2025 4.33M sh
Shares Diluted Q3 2026 · Mar 31, 2025 1.42M sh
Capex Q3 2026 · Mar 31, 2026 $4.91K
Operating Cash Flow Q3 2026 · Mar 31, 2026 −$4.08M
Operating Cash Flow restated Q3 2026 · Mar 31, 2025 −$312.98K
Long Term Debt Q3 2026 · Mar 31, 2026 $55K
Long Term Debt Q3 2026 · Jun 30, 2025 $537.92K
Stockholders Equity Q3 2026 · Mar 31, 2026 $9.83M
Stockholders Equity Q3 2026 · Dec 31, 2025 $10.45M
Stockholders Equity Q3 2026 · Sep 30, 2025 $14.36M
Stockholders Equity Q3 2026 · Jun 30, 2025 $13.91M
Stockholders Equity Q3 2026 · Mar 31, 2025 $18.09M
Stockholders Equity Q3 2026 · Dec 31, 2024 −$4.16M
Stockholders Equity Q3 2026 · Sep 30, 2024 −$4.11M
Stockholders Equity Q3 2026 · Jun 30, 2024 −$3.78M
Current Liabilities Q3 2026 · Mar 31, 2026 $3.48M
Current Liabilities Q3 2026 · Jun 30, 2025 $5.58M
Total Liabilities Q3 2026 · Mar 31, 2026 $3.51M
Total Liabilities Q3 2026 · Jun 30, 2025 $5.73M
Current Assets Q3 2026 · Mar 31, 2026 $8.22M
Current Assets Q3 2026 · Jun 30, 2025 $8.35M
Total Assets Q3 2026 · Mar 31, 2026 $14.33M
Total Assets Q3 2026 · Jun 30, 2025 $19.63M
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.95
Eps Diluted Q3 2026 · Mar 31, 2025 −$12.50
Eps Diluted Q3 2026 · Mar 31, 2025 −$38.62
Eps Basic Q3 2026 · Mar 31, 2026 −$0.28
Eps Basic Q3 2026 · Mar 31, 2026 −$0.95
Eps Basic Q3 2026 · Mar 31, 2025 −$12.50
Eps Basic Q3 2026 · Mar 31, 2025 −$38.62
Sga Expense Q3 2026 · Mar 31, 2026 $6.22M
Sga Expense Q3 2026 · Mar 31, 2026 $14.45M
Sga Expense Q3 2026 · Mar 31, 2025 $53.07M
Sga Expense Q3 2026 · Mar 31, 2025 $53.44M
Rd Expense Q3 2026 · Mar 31, 2026 $169.66K
Rd Expense Q3 2026 · Mar 31, 2026 $249.82K
Rd Expense Q3 2026 · Mar 31, 2025 $54.1K
Rd Expense Q3 2026 · Mar 31, 2025 $170.2K
Net Income Q3 2026 · Mar 31, 2026 −$6.36M
Net Income Q3 2026 · Mar 31, 2026 −$14.29M
Net Income Q3 2026 · Dec 31, 2025 −$3.09M
Net Income Q3 2026 · Sep 30, 2025 −$4.84M
Net Income Q3 2026 · Mar 31, 2025 −$54.07M
Net Income Q3 2026 · Mar 31, 2025 −$54.85M
Net Income Q3 2026 · Dec 31, 2024 −$430.18K
Net Income Q3 2026 · Sep 30, 2024 −$354.31K
Operating Income Q3 2026 · Mar 31, 2026 −$6.4M
Operating Income Q3 2026 · Mar 31, 2026 −$14.73M
Operating Income Q3 2026 · Mar 31, 2025 −$53.13M
Operating Income Q3 2026 · Mar 31, 2025 −$53.63M